Cash and cash equivalents were $530.9M as of June 30, compared to $352.4M as of December 31, 2024. “The second quarter of 2025 saw rapid progress across our category-leading pipeline of ultra-long acting, combinable injectable and oral nutrient-stimulated hormone analogs,” said Whit Bernard, CEO. “We reported positive Phase 1 data from MET-233i, our first-in-class once-monthly amylin candidate, demonstrating exceptional efficacy with favorable tolerability, and enabling a potential first-in-category monthly multi-NuSH combination. Additionally, we completed enrollment in the VESPER-2 and -3 studies with MET-097i ahead of schedule, enabling an accelerated release of interim VESPER-3 tolerability data in tandem with VESPER-1. We remain on track to deliver all of our committed clinical milestones, including initiation of a global Phase 3 program for MET-097i in late 2025.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTSR:
- Metsera price target raised to $45 from $38 at BofA
- Metsera, Inc.: Buy Rating Affirmed Amid Promising Clinical Data and Strategic Positioning
- Metsera initiated with Early-Stage Biotech at Goldman Sachs
- Circle initiated, Charter upgraded: Wall Street’s top analyst calls
- Metsera initiated with an Overweight at Wells Fargo